Which hedge funds own GANX? GAIN THERAPEUTICS INC, Q2 2026 13F holders
7 of the hedge funds tracked by WhaleCreep disclosed a position in GANX (GAIN THERAPEUTICS INC) in their Q2 2026 13F filings, worth $8.9m in total. The largest holder by portfolio weight is Potomac Capital Management, Inc. at 1.4% of its book. 1 manager opened a new position this quarter: Squarepoint Ops LLC. 1 exited: Schonfeld Strategic Advisors LLC.
7tracked managers holding
1opened this quarter
1exited this quarter
Which hedge funds hold GANX? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Potomac Capital Management, Inc. | Q2 2026 | 1.4% | $1.9m | 946,400 | -6% | reduced |
| Gsa Capital Partners LLP | Q2 2026 | 0.1% | $1.3m | 632,131 | 102% | added |
| Dme Capital Management, LP | Q2 2026 | 0.0% | $1.1m | 566,130 | 0% | held |
| Prelude Capital Management, LLC | Q2 2026 | 0.0% | $72.7k | 35,820 | 0% | held |
| Marshall Wace, LLP | Q2 2026 | 0.0% | $3.9m | 1,923,546 | 9% | added |
| Squarepoint Ops LLC | Q2 2026 | 0.0% | $276.8k | 136,359 | – | new |
| Citadel Advisors LLC | Q2 2026 | 0.0% | $313.7k | 154,524 | 521% | added |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 0.0% | $47.5k |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| greenlight | Q4 2023 | 0.1% |
How has hedge fund ownership of GANX changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 7 | $8.9m |
| Q1 2026 | 7 | $7.3m |
| Q4 2025 | 2 | $160.6k |
| Q3 2025 | 1 | $223.2k |
| Q2 2025 | 1 | $169.2k |
| Q3 2024 | 1 | $94.8k |
| Q2 2024 | 1 | $151.9k |
| Q1 2024 | 1 | $176.0k |
| Q4 2023 | 2 | $2.1m |
| Q3 2023 | 2 | $2.1m |
| Q2 2023 | 2 | $2.7m |
| Q1 2023 | 2 | $2.8m |
| Q4 2022 | 2 | $1.8m |
| Q3 2022 | 2 | $1.9m |
| Q2 2022 | 2 | $2.1m |
| Q1 2022 | 1 | $2.2m |
Counts every tracked manager that disclosed GANX in that quarter's filing, including managers that have since stopped filing.